Log in

NASDAQ:XERS - Xeris Pharmaceuticals Stock Price, Forecast & News

$4.05
-0.05 (-1.22 %)
(As of 02/26/2020 05:49 AM ET)
Today's Range
$4.02
Now: $4.05
$4.23
50-Day Range
$4.00
MA: $5.52
$6.39
52-Week Range
$3.84
Now: $4.05
$12.98
Volume376,100 shs
Average Volume594,176 shs
Market Capitalization$109.33 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.45
Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XERS
CUSIPN/A
CIKN/A
Phone844-445-5704

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.46 million
Book Value$3.61 per share

Profitability

Net Income$-60,080,000.00
Net Margins-6,697.33%

Miscellaneous

Employees90
Market Cap$109.33 million
Next Earnings Date3/4/2020 (Estimated)
OptionableNot Optionable

Receive XERS News and Ratings via Email

Sign-up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter.


Xeris Pharmaceuticals (NASDAQ:XERS) Frequently Asked Questions

What is Xeris Pharmaceuticals' stock symbol?

Xeris Pharmaceuticals trades on the NASDAQ under the ticker symbol "XERS."

How were Xeris Pharmaceuticals' earnings last quarter?

Xeris Pharmaceuticals Inc (NASDAQ:XERS) posted its quarterly earnings data on Thursday, November, 7th. The company reported ($1.22) EPS for the quarter, topping the Zacks' consensus estimate of ($1.23) by $0.01. The firm had revenue of $0.32 million for the quarter, compared to analyst estimates of $0.20 million. Xeris Pharmaceuticals had a negative return on equity of 150.08% and a negative net margin of 6,697.33%. View Xeris Pharmaceuticals' Earnings History.

When is Xeris Pharmaceuticals' next earnings date?

Xeris Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Xeris Pharmaceuticals.

What price target have analysts set for XERS?

3 brokerages have issued twelve-month price objectives for Xeris Pharmaceuticals' shares. Their forecasts range from $12.00 to $18.00. On average, they expect Xeris Pharmaceuticals' stock price to reach $16.00 in the next year. This suggests a possible upside of 295.1% from the stock's current price. View Analyst Price Targets for Xeris Pharmaceuticals.

What is the consensus analysts' recommendation for Xeris Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xeris Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Xeris Pharmaceuticals.

What are Wall Street analysts saying about Xeris Pharmaceuticals stock?

Here are some recent quotes from research analysts about Xeris Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Xeris Pharmaceuticals, Inc. produces peptides, proteins, antibodies, molecules, auto-injectors, multi-dose pens and infusion pumps to treat endocrine and metabolic diseases. The company's proprietary formulation technologies consist of XeriSol (TM) and XeriJect(TM). Xeris Pharmaceuticals, Inc. is based in Chicago, United States. " (2/14/2020)
  • 2. Mizuho analysts commented, "We applied a weighted average valuation methodology (DCF+EV/Sales) to derive our $27 PT. Our assumptions include: Launch of the glucagon rescue pen in the U.S. market in 4Q19, with unadjusted peak-sales of $454 mil in 2028 (current PoS: 90%)." (9/10/2019)

Has Xeris Pharmaceuticals been receiving favorable news coverage?

News coverage about XERS stock has trended somewhat negative on Wednesday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Xeris Pharmaceuticals earned a news sentiment score of -1.4 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Xeris Pharmaceuticals.

Who are some of Xeris Pharmaceuticals' key competitors?

What other stocks do shareholders of Xeris Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xeris Pharmaceuticals investors own include Amarin (AMRN), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), Agile Therapeutics (AGRX), Exelixis (EXEL), Amicus Therapeutics (FOLD), Five Prime Therapeutics (FPRX), Heron Therapeutics (HRTX), Kala Pharmaceuticals (KALA) and Omeros (OMER).

Who are Xeris Pharmaceuticals' key executives?

Xeris Pharmaceuticals' management team includes the folowing people:
  • Mr. Paul R. Edick, Pres, CEO & Chairman (Age 63)
  • Mr. Barry M. Deutsch, Chief Financial Officer (Age 54)
  • Mr. John P. Shannon, Exec. VP & COO (Age 57)
  • Dr. Steven J. Prestrelski, Co-Founder & Chief Scientific Officer (Age 55)
  • Ms. Allison Wey, Sr. VP of Investor Relations & Corp. Communications

When did Xeris Pharmaceuticals IPO?

(XERS) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Mizuho Securities was co-manager.

Who are Xeris Pharmaceuticals' major shareholders?

Xeris Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Citigroup Inc. (8.15%), ArrowMark Colorado Holdings LLC (7.14%), State Street Corp (1.85%), Blackstone Group Inc (1.67%), Geode Capital Management LLC (1.31%) and IHT Wealth Management LLC (0.34%). Company insiders that own Xeris Pharmaceuticals stock include Beth Hecht, James E Flynn, John Patrick Shannon Jr, Palmetto Partners, Ltd, Paul R Edick, Redmile Group, Llc and Steven Prestrelski. View Institutional Ownership Trends for Xeris Pharmaceuticals.

Which major investors are selling Xeris Pharmaceuticals stock?

XERS stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Goldman Sachs Group Inc. and Bank of America Corp DE. View Insider Buying and Selling for Xeris Pharmaceuticals.

Which major investors are buying Xeris Pharmaceuticals stock?

XERS stock was bought by a variety of institutional investors in the last quarter, including Citigroup Inc., Blackstone Group Inc, ArrowMark Colorado Holdings LLC, California Public Employees Retirement System, State Street Corp, IHT Wealth Management LLC, Marshall Wace LLP and Marshall Wace North America L.P.. Company insiders that have bought Xeris Pharmaceuticals stock in the last two years include Beth Hecht, James E Flynn, John Patrick Shannon Jr, Palmetto Partners, Ltd, Paul R Edick and Redmile Group, Llc. View Insider Buying and Selling for Xeris Pharmaceuticals.

How do I buy shares of Xeris Pharmaceuticals?

Shares of XERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Xeris Pharmaceuticals' stock price today?

One share of XERS stock can currently be purchased for approximately $4.05.

How big of a company is Xeris Pharmaceuticals?

Xeris Pharmaceuticals has a market capitalization of $109.33 million and generates $2.46 million in revenue each year. The company earns $-60,080,000.00 in net income (profit) each year or ($4.99) on an earnings per share basis. Xeris Pharmaceuticals employs 90 workers across the globe.View Additional Information About Xeris Pharmaceuticals.

What is Xeris Pharmaceuticals' official website?

The official website for Xeris Pharmaceuticals is http://www.xerispharma.com/.

How can I contact Xeris Pharmaceuticals?

Xeris Pharmaceuticals' mailing address is 180 N. LaSalle Street Suite 1810, Chicago IL, 60601. The company can be reached via phone at 844-445-5704 or via email at [email protected]


MarketBeat Community Rating for Xeris Pharmaceuticals (NASDAQ XERS)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  90 (Vote Outperform)
Underperform Votes:  98 (Vote Underperform)
Total Votes:  188
MarketBeat's community ratings are surveys of what our community members think about Xeris Pharmaceuticals and other stocks. Vote "Outperform" if you believe XERS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XERS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel